Document is current
Any future updates will be listed below
-
Authors
Moncrieff, Marc D. https://orcid.org/0000-0003-4492-235X
Lo, Serigne N.
Scolyer, Richard A.
Heaton, Martin J.
Nobes, Jenny P.
Snelling, Andrew P.
Carr, Michael J.
Nessim, Carolyn
Wade, Ryckie
Peach, A. Howard
Kisyova, Rumi
Mason, Jennifer
Wilson, Ewan D.
Nolan, Grant
Pritchard Jones, Rowan
Sondak, Vernon K.
Thompson, John F.
Zager, Jonathan S.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (Practitioner Fellowship (APP1141295), Program Grant (APP1093017))
- License Information
-
More Information
Article History
Received: 31 December 2021
Accepted: 23 March 2022
First Online: 13 May 2022
Disclosure
: MDM has received honoraria to present from Sanofi. RAS has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. Other authors have no conflicts to declare. CN has received honoraria to speak and to be on advisory boards for Novartis, Merck, EMD Sorono and Sanofi. JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc and Novartis. JSZ has received fees for professional services from Merck, Amgen, Novartis, Philogen, Delcath Systems, Castle Biosciences. JSZ also has research funding through institution for Provectus, Castle Biosciences, Neracare, Philogen, Delcath Systems. None of which are pertinent to the current publication.
